Drugs / Bilastine
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07042828 | Apr → Jun 2025 | allergic disease, urticaria | Humanis | Completed | No outcome recorded |
| Phase 1 | NCT03633760 | Aug 2018 → Apr 2019 | — | A.Menarini Asia-Pacific Holdings Pte Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT00572611 | Nov → Dec 2007 | — | Faes Farma, S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00419783 | Aug → Dec 2006 | — | Faes Farma, S.A. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01081574 | Jan 2010 → Jun 2012 | allergic disease, chronic urticaria | Faes Farma, S.A. | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT03231969 | Jul → Oct 2017 | conjunctivitis | Faes Farma, S.A. | Completed | Met primary |
| Phase 2 | NCT00574379 | Dec 2007 → Mar 2008 | conjunctivitis, seasonal allergic rhinitis | Faes Farma, S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00574210 | Oct 2007 → Feb 2008 | seasonal allergic rhinitis | Faes Farma, S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00420082 | Oct → Dec 2006 | seasonal allergic rhinitis | Faes Farma, S.A. | Completed | No outcome recorded |
| Phase 37 trials · 4 met primary · 1 missed | ||||||
| Phase 3 | NCT04810390 | Mar 2021 → Nov 2022 | conjunctivitis | Faes Farma, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT03479307 | Apr → Aug 2018 | eye allergy | Faes Farma, S.A. | Completed | Met primary |
| Phase 3 | NCT01400828 | Jun 2011 → Jun 2013 | seasonal allergic rhinitis | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00421109 | Jul 2006 → Jul 2007 | chronic idiopathic urticaria | Faes Farma, S.A. | Completed | Met primary |
| Phase 3 | NCT00504933 | May → Nov 2005 | seasonal allergic rhinitis | Faes Farma, S.A. | Completed | Met primary |
| Phase 3 | NCT01127620 | May 2004 → Mar 2006 | perennial allergic rhinitis | Faes Farma, S.A. | Completed | Missed primary |
| Phase 3 | NCT01108783 | Apr → Aug 2003 | seasonal allergic rhinitis | Faes Farma, S.A. | Completed | Met primary |
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT02761252 | Apr → Nov 2016 | asthma, seasonal allergic rhinitis | Menarini International Operations Luxembourg SA | Completed | Missed primary |
| Phase 4 | NCT02576041 | Oct → Dec 2015 | allergic rhinitis, urticaria | Menarini International Operations Luxembourg SA | Completed | No outcome recorded |
| Phase 4 | NCT02513290 | Aug 2013 → Aug 2014 | allergic rhinitis | University of Southern Santa Catarina | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT01124123 Comparator | May → Jun 2010 | — | Faes Farma, S.A. | Completed | No outcome recorded |
| Phase 2 | NCT04967092 Comparator | Aug 2021 → Mar 2023 | chronic urticaria | Prof. Lin Zhixiu | Unknown | No outcome recorded |
| Phase 2/3 | NCT01271075 Comparator | Sep 2010 → Aug 2011 | cold urticaria | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 3 | NCT02213367 Comparator | Jul 2014 → Mar 2016 | chronic urticaria | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT02557269 Background | May → Oct 2015 | seasonal allergic rhinitis | Association Asthma, Bulgaria | Unknown | No outcome recorded |
| Phase 4 | NCT01940393 Comparator | Aug → Dec 2013 | urticaria | Grupo de Alergología Clínica y Experimental | Completed | No outcome recorded |
| — | NCT07365683 Comparator | Aug 2025 → Jan 2026 | chronic idiopathic urticaria | Derma Techno Pakistan | Completed | No outcome recorded |
Press releases naming this drug 26 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bilastine | “Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.” NCT04967092 ↗ |
| Known as | Bilastina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742423 ↗ |
| Known as | Bilaxten | “Bilastine (Bilaxten™) is a novel non-sedating H1 receptor antagonist (antihistamine) developed in the dosage form of oral tablets and indicated for the treatment of allergic...” PMID 23529786 ↗ May 20131“To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy,...” NCT07042828 ↗ |
| Known as | Ilaxten | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742423 ↗ |
| Action | Inhibit | “Bilastine is a novel nonsedative H(1)-receptor antagonist” PMID 19860762 ↗ Oct 2009 |
| Modality | Small molecule | — CHEMBL1742423 ↗ |
| Route | Oral | “were taken orally” PMID 19943178 ↗ Nov 2009 |
| Target | HRH1 | “Histamine H1 receptor inverse agonist” CHEMBL1742423 ↗ |